| Size | Price | Stock | Qty |
|---|---|---|---|
| 5mg |
|
||
| 10mg |
|
||
| 100mg | |||
| 250mg | |||
| Other Sizes |
| Targets |
Levadopa Related Compound A does not have a therapeutic target; it is an impurity standard. However, its neurotoxic effects are mediated through its biotransformation by amino acid decarboxylase to a potent catecholamine-selective neurotoxin. This neurotoxin can target catecholaminergic neurons, similar to 6-hydroxydopamine. The compound itself is a derivative of L-DOPA and can interact with enzymes involved in dopamine biosynthesis.
|
|---|---|
| ln Vitro |
In vitro, Levadopa Related Compound A (6-Hydroxy-L-DOPA) serves as an electron-donating unit in luminescent silver nanocluster sensors for the detection of nitro-substituted explosives. It is not typically used for biological activity assays. Its neurotoxic properties have been characterized, and it is known to be biotransformed to a potent neurotoxin. It is primarily used as a reference material for analytical method development.
|
| ln Vivo |
In vivo, exogenously administered 6-Hydroxy-L-DOPA is biotransformed by an amino acid decarboxylase to a highly potent and catecholamine-selective neurotoxin. This neurotoxin can induce neurotoxicity in catecholaminergic systems. The compound's in vivo effects are primarily related to its neurotoxic properties. It is not used as a therapeutic agent but rather as a research tool or impurity standard.
|
| Enzyme Assay |
In vitro assays for Levadopa Related Compound A are typically analytical rather than biological. High-performance liquid chromatography (HPLC) with UV detection is used for quantification and purity assessment. Mass spectrometry (MS) may be used for identification. For biological studies, the compound can be used as a substrate for amino acid decarboxylase to study enzymatic activity and neurotoxin formation.
|
| Cell Assay |
For in vitro cellular assays, Levadopa Related Compound A can be used to study neurotoxicity in neuronal cell cultures. Cells are treated with the compound, and neurotoxin formation is assessed. Cell viability is measured using MTT or LDH release assays. Catecholamine levels may be measured by HPLC to assess neurotoxic effects. However, the compound is primarily used as an analytical reference standard.
|
| Animal Protocol |
In vivo animal studies for Levadopa Related Compound A are typically conducted to study neurotoxicity. The compound is administered to rodents, and neurotoxin formation is assessed. Behavioral and neurochemical endpoints are measured to evaluate neurotoxic effects. However, the compound is primarily used as an impurity standard for quality control rather than for in vivo efficacy studies.
|
| ADME/Pharmacokinetics |
Levadopa Related Compound A has molecular weight of 213.19 g/mol and molecular formula C9H11NO5. It is a brown to black solid. The compound is hygroscopic and air-sensitive. It is sparingly soluble in aqueous acid and water. It is typically stored at -20°C under inert atmosphere. The melting point is >190°C (dec.).
|
| Toxicity/Toxicokinetics |
Levadopa Related Compound A has neurotoxic properties. It is biotransformed to a potent catecholamine-selective neurotoxin. As an impurity standard, it is not intended for therapeutic use. Standard safety precautions should be followed when handling this compound. It may be irritating to skin and eyes. No significant systemic toxicity data is available as it is not used as a therapeutic agent.
|
| References | |
| Additional Infomation |
6-Hydroxy-L-DOPA is an L-α-amino acid formed by introducing an additional hydroxyl substituent at the 6-position of L-DOPA. It is a non-protein L-α-amino acid and a derivative of L-phenylalanine. Functionally, it is related to L-DOPA.
Levadopa Related Compound A (CAS 27244-64-0) is the 6-hydroxy derivative of L-DOPA. It is known as Levodopa EP Impurity A and Levodopa USP Related Compound A. It has neurotoxic properties. It is used as a reference standard for pharmaceutical quality control. It is available for research purposes only. |
| Molecular Formula |
C9H11NO5
|
|---|---|
| Molecular Weight |
213.18
|
| Exact Mass |
213.064
|
| CAS # |
27244-64-0
|
| PubChem CID |
33755
|
| Appearance |
Light brown to brown solid powder
|
| Density |
1.606g/cm3
|
| Boiling Point |
515.2ºC at 760mmHg
|
| Flash Point |
265.4ºC
|
| LogP |
0.458
|
| Hydrogen Bond Donor Count |
5
|
| Hydrogen Bond Acceptor Count |
6
|
| Rotatable Bond Count |
3
|
| Heavy Atom Count |
15
|
| Complexity |
235
|
| Defined Atom Stereocenter Count |
1
|
| SMILES |
OC([C@H](CC1=CC(O)=C(O)C=C1O)N)=O
|
| InChi Key |
YLKRUSPZOTYMAT-YFKPBYRVSA-N
|
| InChi Code |
InChI=1S/C9H11NO5/c10-5(9(14)15)1-4-2-7(12)8(13)3-6(4)11/h2-3,5,11-13H,1,10H2,(H,14,15)/t5-/m0/s1
|
| Chemical Name |
(2S)-2-amino-3-(2,4,5-trihydroxyphenyl)propanoic acid
|
| Synonyms |
L-Hydroxydopa; Levadopa Related Compound A; 6-Hydroxydopa, L-
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 4.6909 mL | 23.4544 mL | 46.9087 mL | |
| 5 mM | 0.9382 mL | 4.6909 mL | 9.3817 mL | |
| 10 mM | 0.4691 mL | 2.3454 mL | 4.6909 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
